The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort.
 
Sujana Movva
Consulting or Advisory Role - Genmab
Research Funding - Ascentage Pharma Group (Inst); Hutchison MediPharma (Inst); Trillium Therapeutics (Inst)
 
Mihaela Druta
Consulting or Advisory Role - AADi; Adaptimmune; Decipher Biosciences
Speakers' Bureau - AADi; Deciphera
Travel, Accommodations, Expenses - AADi
 
Lara E. Davis
Consulting or Advisory Role - Daiichi Sankyo; Regeneron; SpringWorks Therapeutics
Research Funding - Bayer (Inst); BTG (Inst); Eisai (Inst); Novartis (Inst)
 
Varun Monga
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Hutchison MediPharma (Inst); Oblato (Inst); Pfizer (Inst); Prelude Therapeutics (Inst)
Travel, Accommodations, Expenses - Cogent Biosciences
 
Mohammed M. Milhem
Consulting or Advisory Role - Exicure
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)
 
Howard Harry Bailey
Consulting or Advisory Role - Forte Pharma
Research Funding - Pfizer
 
Rashmi Chugh
Consulting or Advisory Role - Deciphera; Epizyme; Jazz Pharmaceuticals
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Cogent Biosciences (Inst); Cornerstone Pharmaceuticals (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); Janssen (Inst); Mundipharma (Inst); Pfizer (Inst); Plexxikon (Inst); PTC Therapeutics (Inst); Qilu Puget Sound Biotherapeutics (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Wolters Kluwer
Expert Testimony - Meyers Law (Inst)
 
Ingmar Bruns
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Victoria E Allgood
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma